Mutational analysis in chronic myeloid leukemia: when and what to do?BRANFORD, Susan; HUGHES, Timothy P.Current opinion in hematology. 2011, Vol 18, Num 2, pp 111-116, issn 1065-6251, 6 p.Article

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemiaHUGHES, Timothy; BRANFORD, Susan.Blood reviews. 2006, Vol 20, Num 1, pp 29-41, issn 0268-960X, 13 p.Article

Practical Considerations for Monitoring Patients With Chronic Myeloid LeukemiaBRANFORD, Susan; HUGHES, Timothy P.Seminars in hematology. 2010, Vol 47, Num 4, pp 327-334, issn 0037-1963, 8 p.Article

Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneBRANFORD, Susan; HUGHES, Timothy P; RUDZKI, Zbigniew et al.British journal of haematology. 2002, Vol 117, Num 4, pp 875-877, issn 0007-1048Article

Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome―Positive Chronic Myeloid Leukemia in Chronic Phase Treated With NilotinibBRANFORD, Susan; KIM, Dong-Wook; HOCHHAUS, Andreas et al.Journal of clinical oncology. 2012, Vol 30, Num 35, pp 4323-4329, issn 0732-183X, 7 p.Article

Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapyHUGHES, Timothy P; BRANFORD, Susan; COONEY, Julian et al.Blood. 2008, Vol 112, Num 10, pp 3865-3873, issn 0006-4971, 9 p.Article

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLWHITE, Deborah; SAUNDERS, Verity; LYONS, A. Bruce et al.Blood. 2005, Vol 106, Num 7, pp 2520-2526, issn 0006-4971, 7 p.Article

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profilePARKER, Wendy T; HO, Musei; SCOTT, Hamish S et al.Blood. 2012, Vol 119, Num 10, pp 2234-2238, issn 0006-4971, 5 p.Article

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaESPOSITO, Nicola; COLAVITA, Irene; WHITE, Deborah et al.Blood. 2011, Vol 118, Num 13, pp 3634-3644, issn 0006-4971, 11 p.Article

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. CommentaryGUILHOT, Francois; APPERLEY, Jane; HEIM, Dominik et al.Blood. 2007, Vol 109, Num 10, issn 0006-4971, 4110, 4143-4150 [9 p.]Article

Dynamics of chronic myeloid leukaemiaMICHOR, Franziska; HUGHES, Timothy P; IWASA, Yoh et al.Nature (London). 2005, Vol 435, Num 7046, pp 1267-1270, issn 0028-0836, 4 p.Article

Molecular monitoring of chronic myeloid leukemiaHUGHES, Tim; BRANFORD, Susan.Seminars in hematology. 2003, Vol 40, Num 2, pp 62-68, issn 0037-1963, 7 p., SUP2Conference Paper

Sensitive Detection of BCR-ABL1 Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent TherapyPARKER, Wendy T; LAWRENCE, Rebecca M; HO, Musei et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4250-4259, issn 0732-183X, 10 p.Article

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCORTES, Jorge E; BACCARANI, Michele; MOIRAGHI, Beatriz et al.Journal of clinical oncology. 2010, Vol 28, Num 3, pp 424-430, issn 0732-183X, 7 p.Article

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALLTOJO, Arinobu; USUKI, Kensuke; MIYAMURA, Koichi et al.International journal of hematology. 2009, Vol 89, Num 5, pp 679-688, issn 0925-5710, 10 p.Article

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. CommentaryGOLDMAN, John; CORTES, Jorge; APPERLEY, Jane et al.Blood. 2007, Vol 109, Num 8, issn 0006-4971, 3128,3207-3213 [8 p.]Article

BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First -Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity CriteriaBRANFORD, Susan; SEYMOUR, John F; GRIGG, Andrew et al.Clinical cancer research. 2007, Vol 13, Num 23, pp 7080-7085, issn 1078-0432, 6 p.Article

BCR-ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib TreatmentSTEIN, Andrew M; BOTTINO, Dean; MODUR, Vijay et al.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6812-6821, issn 1078-0432, 10 p.Article

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseHUGHES, Timothy; SAGLIO, Giuseppe; KIM, Dongho et al.Journal of clinical oncology. 2009, Vol 27, Num 25, pp 4204-4210, issn 0732-183X, 7 p.Article

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutationsBRANFORD, Susan; RUDZKI, Zbigniew; CATALANO, John et al.Blood. 2004, Vol 104, Num 9, pp 2926-2932, issn 0006-4971, 7 p.Article

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBRANFORD, Susan; RUDZKI, Zbigniew; JOSKE, David et al.Blood. 2003, Vol 102, Num 1, pp 276-283, issn 0006-4971, 8 p.Article

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHUGHES, Tim P; KAEDA, Jaspal; RADICH, Jerald P et al.The New England journal of medicine. 2003, Vol 349, Num 15, pp 1423-1432, issn 0028-4793, 10 p.Article

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyBACCARANI, Michele; DRUKER, Brian J; HUGHES, Timothy P et al.International journal of hematology. 2014, Vol 99, Num 5, pp 616-624, issn 0925-5710, 9 p.Article

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)HUGHES, Timothy P; HOCHHAUS, Andreas; RUDOLTZ, Marc S et al.Blood. 2010, Vol 116, Num 19, pp 3758-3765, issn 0006-4971, 8 p.Article

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMÜLLER, Martin C; CORTES, Jorge E; MUKHOPADHYAY, Jaydip et al.Blood. 2009, Vol 114, Num 24, pp 4944-4953, issn 0006-4971, 10 p.Article